Mylan’s Pay for CEO Bresch Grates on Lawmakers, Many Investors

  • Company touts ‘strong support’; voting tells another story
  • Executive scolded for ‘lavish compensation’ in hearing

Mylan CEO: Reformulating EpiPen to Have Longer Shelf Life

Mylan NV Chief Executive Officer Heather Bresch was lambasted at a congressional hearing this week for taking home tens of millions of dollars as the company raised the price on its EpiPen allergy shot. Some investors have been critical of Mylan’s executive compensation for years.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.